ArticleCancer2012
Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative.
Article in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Statin use is not associated with reduced risk of skin cancer: a meta-analysis.British journal of cancer · 2014Pooled it
- A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.Cancer prevention research (Philadelphia, Pa.) · 2014Trial
- The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with In Situ or Early-Stage Invasive Breast Cancer.International journal of molecular sciences · 2024Article
- Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.BMC cancer · 2024Article
- Hispanic adults with type 2 diabetes mellitus using lipid-lowering agents have better periodontal health than non-users.Therapeutic advances in chronic disease · 2023Article
- Low-Dose Atorvastatin has Promoting Effect on Melanoma Tumor Growth and Angiogenesis in Mouse Model.Advanced biomedical research · 2023Article
- Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype.Clinical, cosmetic and investigational dermatology · 2022Review
- Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.The Journal of investigative dermatology · 2021Article
- Review
- An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort.Cancer medicine · 2018Article
- Statin use and risk of skin cancer.Journal of the American Academy of Dermatology · 2018Article
- An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.Gynecologic oncology · 2018Article
- Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?Current atherosclerosis reports · 2016Review
- Statin use and all-cancer survival: prospective results from the Women's Health Initiative.British journal of cancer · 2016Article
- Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative.Cancer causes & control : CCC · 2016Article
- Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.British journal of cancer · 2016Observational
- Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.Melanoma research · 2015Article
- Impact of cholesterol on disease progression.BioMedicine · 2015Article
- Autocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells.British journal of pharmacology · 2014Article
- Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.Cancer medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMelanoma is the most lethal form of skin cancer, with an estimated 68,130 new cases and 8700 deaths in the United States in 2010. The increasing incidence and high death rate associated with metastatic disease support the need to focus on prevention. The authors used data from the Women's Health Initiative (WHI) to assess whether 3-hydroxy-3 methylglutaryl coenzyme A inhibitors (statins) are associated with a decreased risk of melanoma.
methodsThe study population consisted of 119,726 postmenopausal white women, in which 1099 cases of malignant melanoma were identified over an average (± standard deviation) of 11.6 ± 3.2 years. All diagnoses were confirmed by medical record review and pathology reports. Information on statin use was collected at baseline and during follow-up. Self-administered and interview-administered questionnaires were used to collect information on other risk factors. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Analyses investigated the association of any statin use, type, potency, lipophilic status, and duration of use with melanoma.
resultsStatins were used by 8824 women (7.4%) at baseline. The annualized rate of melanoma was 0.09% among statin users and 0.09% among nonusers The multivariable adjusted HR for statin users compared with nonusers was 1.14 (95% CI, 0.91-1.43). There were no significant differences in risk based on statin type, potency, category, duration, or in time-dependent models.
conclusionsThere was no significant association between statin use and melanoma risk among postmenopausal women in the WHI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.